Ceramide synthase 6 plays a critical role in the development of experimental autoimmune encephalomyelitis

Journal of Immunology

Volumn 188, Issue 11, 2012, Pages 5723-5733

  Schiffmann, Susanne ^a   Ferreiros, Nerea ^a   Birod, Kerstin ^a   Eberle, Max ^a   Schreiber, Yannick ^a   Pfeilschifter, Waltraud ^b   Ziemann, Ulf ^b   Pierre, Sandra ^a   Scholich, Klaus ^a   Grösch, Sabine ^a   Geisslinger, Gerd ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; CERAMIDE SYNTHASE 6; CYCLOSERINE; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PALMITIC ACID; SPHINGOSINE ACYLTRANSFERASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DOWN REGULATION; FEMALE; HUMAN; IMMUNOPATHOLOGY; LUMBAR SPINAL CORD; MACROGLIA; MACROPHAGE; MALE; MONOCYTE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; UPREGULATION;

ADULT; AGED; ANIMALS; CELLS, CULTURED; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; INFLAMMATION; INTERFERON-GAMMA; MACROPHAGES, PERITONEAL; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; NITRIC OXIDE; SPHINGOSINE N-ACYLTRANSFERASE; YOUNG ADULT;

EID: 84862102041     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1103109     Document Type: Article

References (44)

1. McFarland, H. F., and R. Martin. 2007. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 8: 913-919. (Pubitemid 47300005)
2. Willenborg, D. O., M. Staykova, S. Fordham, N. O'Brien, and D. Linares. 2007. The contribution of nitric oxide and interferon gamma to the regulation of the neuro-inflammation in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 191: 16-25. (Pubitemid 350060995)
3. Lim, S.-Y., and C. Constantinescu. 2010. TNF-a: a paradigm of paradox and complexity in multiple sclerosis and its animal models. Open Autoimmun. J. 2: 160-170.
4. Hooper, D. C., O. Bagasra, J. C. Marini, A. Zborek, S. T. Ohnishi, R. Kean, J. M. Champion, A. B. Sarker, L. Bobroski, J. L. Farber, et al. 1997. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. Proc. Natl. Acad. Sci. USA 94: 2528-2533. (Pubitemid 27136909)
5. Selmaj, K., W. Papierz, A. Glabiński, and T. Kohno. 1995. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J. Neuroimmunol. 56: 135-141.
6. Rejdak, K., M. J. Eikelenboom, A. Petzold, E. J. Thompson, Z. Stelmasiak, R. H. Lazeron, F. Barkhof, C. H. Polman, B. M. Uitdehaag, and G. Giovannoni. 2004. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology 63: 1439-1445. (Pubitemid 39426278)
7. Hannun, Y. A., and L. M. Obeid. 2008. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat. Rev. Mol. Cell Biol. 9: 139-150. (Pubitemid 351158911)
8. Jana, A., and K. Pahan. 2010. Sphingolipids in multiple sclerosis. Neuromolecular Med. 12: 351-361.
9. Ben-David, O., and A. H. Futerman. 2010. The role of the ceramide acyl chain length in neurodegeneration: involvement of ceramide synthases. Neuromolecular Med. 12: 341-350.
10. Zeidan, Y. H., and Y. A. Hannun. 2010. The acid sphingomyelinase/ceramide pathway: biomedical significance and mechanisms of regulation. Curr. Mol. Med. 10: 454-466.
11. Becker, K. A., J. Riethmüller, Y. Zhang, and E. Gulbins. 2010. The role of sphingolipids and ceramide in pulmonary inflammation in cystic fibrosis. Open Respir. Med. J. 4: 39-47.
12. Billiau, A., and P. Matthys. 2001. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J. Leukoc. Biol. 70: 849-860. (Pubitemid 33151123)
13. Sundaram, K. S., and M. Lev. 1989. The long-term administration of L-cycloserine to mice: specific reduction of cerebroside level. Neurochem. Res. 14: 245-248. (Pubitemid 19132454)
14. Schiffmann, S., T. J. Maier, I. Wobst, A. Janssen, H. Corban-Wilhelm, C. Angioni, G. Geisslinger, and S. Grösch. 2008. The anti-proliferative potency of celecoxib is not a class effect of coxibs. Biochem. Pharmacol. 76: 179-187.
15. Schiffmann, S., S. Ziebell, J. Sandner, K. Birod, K. Deckmann, D. Hartmann, S. Rode, H. Schmidt, C. Angioni, G. Geisslinger, and S. Grösch. 2010. Activation of ceramide synthase 6 by celecoxib leads to a selective induction of C16: 0-ceramide. Biochem. Pharmacol. 80: 1632-1640.
16. Laviad, E. L., L. Albee, I. Pankova-Kholmyansky, S. Epstein, H. Park, A. H. Merrill, Jr., and A. H. Futerman. 2008. Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate. J. Biol. Chem. 283: 5677-5684.
17. Chiang, S. H., M. Bazuine, C. N. Lumeng, L. M. Geletka, J. Mowers, N. M. White, J. T. Ma, J. Zhou, N. Qi, D. Westcott, et al. 2009. The protein kinase IKKepsilon regulates energy balance in obese mice. Cell 138: 961-975.
18. Nath, N., M. Khan, M. K. Paintlia, I. Singh, M. N. Hoda, and S. Giri. 2009. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J. Immunol. 182: 8005-8014.
19. Schiffmann, S., J. Sandner, R. Schmidt, K. Birod, I. Wobst, H. Schmidt, C. Angioni, G. Geisslinger, and S. Grösch. 2009. The selective COX-2 inhibitor celecoxib modulates sphingolipid synthesis. J. Lipid Res. 50: 32-40.
20. Schiffmann, S., J. Sandner, K. Birod, I. Wobst, C. Angioni, E. Ruckhäberle, M. Kaufmann, H. Ackermann, J. Lötsch, H. Schmidt, et al. 2009. Ceramide synthases and ceramide levels are increased in breast cancer tissue. Carcinogenesis 30: 745-752.
21. Green, L. C., D. A. Wagner, J. Glogowski, P. L. Skipper, J. S. Wishnok, and S. R. Tannenbaum. 1982. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal. Biochem. 126: 131-138. (Pubitemid 13203451)
22. Ajami, B., J. L. Bennett, C. Krieger, K. M. McNagny, and F. M. Rossi. 2011. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat. Neurosci. 14: 1142-1149.
23. Domingues, H. S., M. Mues, H. Lassmann, H. Wekerle, and G. Krishnamoorthy. 2010. Functional and pathogenic differences of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. PLoS ONE 5: e15531.
24. Mitrovic, B., L. J. Ignarro, S. Montestruque, A. Smoll, and J. E. Merrill. 1994. Nitric oxide as a potential pathological mechanism in demyelination: its differential effects on primary glial cells in vitro. Neuroscience 61: 575-585. (Pubitemid 24240305)
25. Merrill, J. E., L. J. Ignarro, M. P. Sherman, J. Melinek, and T. E. Lane. 1993. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J. Immunol. 151: 2132-2141. (Pubitemid 23235686)
26. Vartanian, T., Y. Li, M. Zhao, and K. Stefansson. 1995. Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Mol. Med. 1: 732-743. (Pubitemid 3013083)
27. Pál, E., T. Tabira, T. Kawano, M. Taniguchi, S. Miyake, and T. Yamamura. 2001. Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of Valpha 14 NK T cells. J. Immunol. 166: 662-668. (Pubitemid 32038491)
28. Nixon, G. F. 2009. Sphingolipids in inflammation: pathological implications and potential therapeutic targets. Br. J. Pharmacol. 158: 982-993.
29. Grösch, S., S. Schiffmann, and G. Geisslinger. 2012. Chain length-specific properties of ceramides. Prog. Lipid Res. 51: 50-62.
30. Pannu, R., J. S. Won, M. Khan, A. K. Singh, and I. Singh. 2004. A novel role of lactosylceramide in the regulation of lipopolysaccharide/interferon- gamma-mediated inducible nitric oxide synthase gene expression: implications for neuroinflammatory diseases. J. Neurosci. 24: 5942-5954. (Pubitemid 38859392)
31. Yang, M. S., I. Jou, H. Inn-Oc, and E. Joe. 2001. Sphingomyelinase but not ceramide induces nitric oxide synthase expression in rat brain microglia. Neurosci. Lett. 311: 133-136. (Pubitemid 32900623)
32. Gordon, S., and P. R. Taylor. 2005. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5: 953-964. (Pubitemid 41746764)
33. Axtell, R. C., B. A. de Jong, K. Boniface, L. F. van der Voort, R. Bhat, P. De Sarno, R. Naves, M. Han, F. Zhong, J. G. Castellanos, et al. 2010. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat. Med. 16: 406-412.
34. Kim, S., A. J. Steelman, Y. Zhang, H. C. Kinney, and J. Li. 2012. Aberrant upregulation of astroglial ceramide potentiates oligodendrocyte injury. Brain Pathol. 22: 41-57.
35. Weber, M. S., M. Starck, S. Wagenpfeil, E. Meinl, R. Hohlfeld, and C. Farina. 2004. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 127: 1370-1378. (Pubitemid 38745515)
36. Gayo, A., L. Mozo, A. Suárez, A. Tuñón, C. Lahoz, and C. Gutiérrez. 1999. Interferon beta-1b treatment modulates TNFalpha and IFNgamma spontaneous gene expression in MS. Neurology 52: 1764-1770. (Pubitemid 29260887)
37. Kumagai, K., S. Yasuda, K. Okemoto, M. Nishijima, S. Kobayashi, and K. Hanada. 2005. CERT mediates intermembrane transfer of various molecular species of ceramides. J. Biol. Chem. 280: 6488-6495. (Pubitemid 40341197)
38. van Echten-Deckert, G., and T. Herget. 2006. Sphingolipid metabolism in neural cells. Biochim. Biophys. Acta 1758: 1978-1994. (Pubitemid 44879360)
39. Mullen, T. D., Y. A. Hannun, and L. M. Obeid. 2012. Ceramide synthases at the centre of sphingolipid metabolism and biology. Biochem. J. 441: 789-802.
40. Elsen, L., R. Betz, G. Schwarzmann, K. Sandhoff, and G. van Echten-Deckert. 2002. Identification of ceramide binding proteins in neuronal cells: a critical point of view. Neurochem. Res. 27: 717-727.
41. Wheeler, D., V. V. Bandaru, P. A. Calabresi, A. Nath, and N. J. Haughey. 2008. A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain 131: 3092-3102.
42. Nikić, I., D. Merkler, C. Sorbara, M. Brinkoetter, M. Kreutzfeldt, F. M. Bareyre, W. Brück, D. Bishop, T. Misgeld, and M. Kerschensteiner. 2011. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat. Med. 17: 495-499.
43. Steinman, L. 2001. Multiple sclerosis: a two-stage disease. Nat. Immunol. 2: 762-764.
44. Hendriks, J. J., C. E. Teunissen, H. E. de Vries, and C. D. Dijkstra. 2005. Macrophages and neurodegeneration. Brain Res. Brain Res. Rev. 48: 185-195. (Pubitemid 40585749)